case-study
Because of the Covid pandemic, there has been a tremendous global shift to digital practically overnight. Content marketing was not an exception, and the pharmaceutical and life science companies that were reluctant to adapt to this change suddenly found themselves on the line. Our client reached out to us to streamline their content delivery in order to stay competitive in this new reality.
A Belgium-based biotechnology company specializing in the development and commercialization of innovative drugs.
The solution was launched globally in 2021 and subsequently distributed across all ten markets of the client.
The biotechnology company wanted to standardize their content delivery process. They aimed to produce engaging and relevant content at scale, while reducing time-to-market and operational costs. To achieve these goals, they initiated a Request for Proposal (RFP) for a content factory (CF). Viseven emerged as the winner among all participants.
Our client needed to gain a competitive edge in new markets where customers already had trust in local biotechnology companies. Our team had to launch persuasive content campaigns that would entice HCPs to consider changing their partners.
Viseven helped the client to build a CF to produce personalized, meaningful content on a large scale. We used the modular approach to shrink content production costs, ensure message consistency, and accelerate the medical legal regulatory (MLR) process. To effectively connect with the target audience, we strategically used multiple channels, such as eDetailers, emails, landing pages, and banners.
CRM and CLM – Veeva CRM & CLM
Approval – Veeva Vault PromoMats
Reporting – Veeva CRM MyInsights
Marketing automation – Salesforce Marketing Cloud
Web – Adobe Experience Manager